Actively Recruiting
Endometriosis Transcriptomic Cell Atlas
Led by University Hospital, Toulouse · Updated on 2025-04-10
92
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Toulouse
Lead Sponsor
I
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Endometriosis is an estrogen-dependent, chronic inflammatory gynecologic disease affecting women of reproductive age, with a therapeutic wandering of 6 to 10 years. A better understanding of the initiation phase is a major challenge to improve diagnosis and treatment. The most widely accepted hypothesis to explain the formation of endometriotic lesions is the tubal retrograde reflux during menstruation. However, only 10% of the reproductive age women will develop endometriosis while 90% of women experience retrograde menstruation. This raises the question of the stem cells present in the endometrium and menstrual reflux of these patients, but also of both the peritoneal microenvironment and the estrogenic local signaling which allow the implantation of these lesions.
CONDITIONS
Official Title
Endometriosis Transcriptomic Cell Atlas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged over 18 and under 45 years
- Patients with multiple endometriosis sites (superficial, deep, and endometriomas) requiring surgery for painful symptoms and stage III or IV endometriosis with infertility
- Healthy patients aged 18 to 45 undergoing tubal ligation surgery
- Healthy patients aged 18 to 45 undergoing hysterectomy for benign causes not related to endometriosis or adenomyosis
- Patients operated strictly during menstruation
- Participants not on hormonal treatment for at least 2 months
- Participants who have signed informed consent
- Participants with membership in a Social Security scheme or equivalent
You will not qualify if you...
- Patients with endometriosis not treated surgically
- Patients on hormonal treatment at surgery time or within 2 months prior
- Patients with adenomyosis only
- Healthy patients undergoing hysterectomy for infectious or malignant causes
- Patients under legal protection measures (guardianship, curatorship, safeguard of justice)
- Patients with positive HIV, HTLV, hepatitis B or C serology
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Toulouse
Toulouse, France
Actively Recruiting
Research Team
E
Elodie CHANTALAT, MD
CONTACT
F
Françoise LENFANT, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here